PT  - JOURNAL ARTICLE
AU  - Barbeau, A.
AU  - Roy, M.
AU  - Kastin, A. J.
TI  - Double-blind evaluation of oral L-prolyl-Lleucyl-glycine amide in Parkinson's disease
DP  - 1976 Jan 24
TA  - Canadian Medical Association Journal
PG  - 120--122
VI  - 114
IP  - 2
4099  - http://www.cmaj.ca/content/114/2/120.short
4100  - http://www.cmaj.ca/content/114/2/120.full
SO  - CMAJ1976 Jan 24; 114
AB  - A 4-month double-blind study comparing the effect of increasing oral doses (up to 1.0 g daily) of synthetic L-proyl-L-leucyl-glycine amide (PLG) and placebo in 20 parkinsonian patients showed no significant improvement in objective scores of functional disability. However, important trends and some significant results were observed with the lower doses of PLG. These essentially negative results may be attributed to poor intestinal absorption of the compound, a short biologic half-life in the blood, or administration of oral doses that were much higher than required, or a combination of factors. In further studies with this peptide, which are encouraged, the intravenous route should be used until the question of intestinal absorption is resolved.